Gefitinib Accord

Gefitinib Accord is an oral medication used to treat certain types of cancer. This pharmaceutical is manufactured by Accord Healthcare B.V. and is designed for targeted therapy.

Gefitinib Accord is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific genetic markers. It works by targeting and inhibiting the growth of cancer cells. Patients often wonder, 'What is Gefitinib used for?' and the answer lies in its role as a targeted therapy for advanced NSCLC.

Common effects of Gefitinib Accord may include skin rash, diarrhea, and appetite loss. Some users may also experience dry skin or nausea. These effects can vary in intensity and duration among individuals.

Gefitinib Accord should be handled with care, especially by those with pre-existing medical conditions. It is important to follow the advice of a healthcare professional regarding its use. Pregnant women and individuals with certain allergies should exercise caution.

Gefitinib Accord may interact with other medications, including those that are metabolized by the liver. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect its efficacy.